Loading...
•
Sep 30, 2020
Precigen Q3 2020 Earnings Report
Precigen reported results for Q3 2020, showing increased revenues and reduced net loss compared to the same quarter last year.
Key Takeaways
Precigen reported a revenue increase of 29% to $23.6 million and a reduced net loss from continuing operations of $29.5 million, compared to $49.1 million in the third quarter of 2019. The company highlighted progress in its clinical pipeline, including the dosing of the first patient in the PRGN-2009 Phase I/II trial and advancements in the UltraPorator system.
Total revenues increased by 29% to $23.6 million compared to Q3 2019.
Net loss from continuing operations decreased to $29.5 million, an improvement from $49.1 million in Q3 2019.
The first patient was dosed in the Phase I/II trial for PRGN-2009 AdenoVerse™ Immunotherapy.
Precigen's UltraPorator system was cleared by the FDA as a manufacturing device for its UltraCAR-T manufacturing process.
Precigen
Precigen
Precigen Revenue by Segment
Revenue by Segment
Product revenues Revenue
CapyFin.comService revenues Revenue
CapyFin.comOther revenues Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income